Answers are grounded in this paper and cite their sources.
The trial met its primary objective of noninferiority in AHV and further showed superiority of lonapegsomatropin compared to daily somatropin, with similar safety, in treatment-naïve children with GHD.
No takes yet. Share an insight, caveat, or question.
Thornton et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: